# Adheroza: regulatory provenance and presentation evidence

Assessment date: 12 September 2026. AI source assessment; no human adjudication, production mutation or Tier 1 approval.

**The supported regulatory relationship can be made explicit now. The existing exact-presentation candidates cannot be marked complete without changing their question.** Both cases concern Canadian DIN 02550989, drug code 103974, Adheroza 420 mg vial co-packed with diluent.

## What the sources establish

1. Health Canada's original [NOC33930](https://health-products.canada.ca/noc-ac/nocInfo?no=33930) is dated 20 August 2024 and explicitly includes both DIN 02550989 (420 mg/vial) and DIN 02550970 (150 mg/vial), under one Adheroza New Drug Submission. The newly captured HTML binds the 420 mg block by DIN; block order varies, so a parser must not depend on its ordinal position.
2. The retained [Canadian SBD](https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1736954230750) names DIN 02550989, control 275910 and authorization date 20 August 2024. It identifies Adheroza as HLX02 and cites HLX02-HV01 Part 2 as comparative pharmacokinetic evidence and HLX02-BC01 as comparative clinical evidence. The retained registry study identifiers equal those exact sponsor codes: [NCT02581748](https://clinicaltrials.gov/study/NCT02581748) and [NCT03084237](https://clinicaltrials.gov/study/NCT03084237). The conclusion that these are citations in the selected DIN's Canadian approval follows from this explicit document-and-identifier chain.
3. Newly captured [NOC37260](https://health-products.canada.ca/noc-ac/nocInfo?no=37260), dated 24 March 2026, describes an Adheroza SNDS for adding a diluent. Its 150 mg and 420 mg entries have DIN recorded as Not Applicable. This is a separate regulatory activity, not a fresh initial approval or a direct DIN binding by itself.
4. A newly captured [INESSS report published 28 July 2026](https://www.bibliotheque.assnat.qc.ca/DepotNumerique_v2/AffichageFichier.aspx?idf=334970), physical page 8, identifies Adheroza 420 mg IV powder and the 24 March 2026 NOC with control 297590. That page was visually checked. Page 10 cites the March 2026 Canadian monograph. This provides independent Canadian presentation context and a submission-control lead; it does not name the two trial IDs or give a 150-to-420 mg manufacturing comparison.
5. The [manufacturer's Canadian approval announcement](https://www.henlius.com/en/NewsDetails-4691-26.html) confirms HLX02's Canadian brand and the development package. It does not provide the missing exact presentation bridge.

## What remains unestablished

The inspected HV01 and BC01 trial records describe HLX02 150 mg material. These sources do not establish use of the later Canadian 420 mg co-pack by trial participants or provide an explicit applicable manufacturing/presentation comparability bridge. Neither shared ingredients, equal reconstituted concentration, nor another jurisdiction's 420 mg label supplies that missing evidence.

The INESSS comparison of 420 mg and 440 mg presentations is not a 150-to-420 mg trial-material bridge. Do not transfer the report's comparison into a trial identity conclusion.

## Exact product change proposed

Expose a separate, typed fact labelled **Cited in the Canadian Adheroza approval** on each of the two study cards. Show the official SBD and exact registry sponsor-study-code chain, with a separate line: **Trial presentation: 150 mg HLX02 vial. Selected Canadian presentation: 420 mg vial with diluent. Connection between these presentations: not established in the inspected sources.**

The machine-readable proposal `regulatory-citation-facts.proposal.json` includes the exact DIN, drug code, trial ID, source hashes and pointers. It is source evidence, not an independent human approval or a verified exact-presentation match. Keep it outside the Tier 1 comparison gate and do not change the existing candidate decision state.

This makes the available relationship usable and makes the residual gap specific. It does not weaken the existing four-tier matcher or describe an unresolved presentation as equivalent.

## Candidate scope audit

`completion-assessment/production-import-v3.json` asks whether the source chain establishes the exact product within arm, cohort, formulation and regulatory scope. Both `missing_evidence` arrays expressly require an applicable 150-to-420 mg bridge. Consequently these unchanged packets remain incomplete.

A small metadata correction is warranted: both `needed_to_resolve` fields currently ask for a protocol and cohort reconciliation to an SBD PK/PD analysis. The BC01 case is a clinical efficacy trial; the protocol has already been obtained and its 150 mg presentation identified. Replace this stale generic request with:

- HV01: Obtain an applicable regulator/manufacturer passage connecting the HLX02 150 mg material used in HV01 Part 2 to the Canadian Adheroza 420 mg presentation; preserve the Part 2 and HLX02 subgroup boundaries.
- BC01: Obtain an applicable regulator/manufacturer passage connecting the HLX02 150 mg material used in BC01 to the Canadian Adheroza 420 mg presentation; preserve the HLX02 plus separately supplied docetaxel arm and exclude the comparator.

Any candidate edit must regenerate its source/scope binding and pass the existing validator. The proposal does not perform that mutation. Recording a structured KIT-versus-powder interpretation can close the separate vocabulary issue, but it cannot close the material-comparability gap.

## Specific external route if the exact-presentation question must be closed

Health Canada's [clinical-information request form](https://clinical-information.canada.ca/request-drug-clinical-information) is an official route for the original NDS 275910 and relevant clinical material for SNDS 297590. The [release guidance](https://www.canada.ca/en/health-canada/services/drug-health-product-review-approval/profile-public-release-clinical-information-guidance/document.html), section 2.2, covers clinical overviews, summaries and study reports, while chemistry/manufacturing information can remain confidential. Therefore an ordinary clinical-information request cannot be promised to obtain a CMC bridge.

The prepared request should seek a citable public regulator/manufacturer statement identifying whether clinical material from HV01 Part 2 and BC01 supports the Canadian 420 mg vial and whether the 2026 diluent addition changed the active-drug presentation. Ask for the applicable source and section, rather than asking the recipient to assert equivalence without evidence. No request or message was sent.

## Evidence retention and limits

- Five new raw captures: manufacturer announcement, Quebec viewer, INESSS PDF, and two Health Canada NOC HTML pages. `new-source-receipts.json` records URL, final URL, time, byte count and SHA-256.
- Six retained SBD/registry/monograph/protocol source hashes reverified. `retained-source-integrity.json` preserves paths and locators.
- The previously captured NOC product index was rehashed and its four relevant rows selected into `retained-noc-index-binding.json`.
- NOC web rendering returned transient 502 responses; standard direct acquisition succeeded with HTTP 200. No access-denied page was bypassed. The EMA RMP request returned 429 and was not retried through another client. The Clinical Information portal root returned 502; no complete portal inventory claim is made.
- The exact-presentation gap remains open; no assertion is made that public evidence does not exist anywhere. No human review or patient-level presentation exposure was established.